FDA D.I.S.C.O. Burst Edition: Breyanzi (lisocabtagene maraleucel)
Release Date:
Listen to a soundcast of the Feb 5th 2021 FDA approval of Breyanzi for treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy
FDA D.I.S.C.O. Burst Edition: Breyanzi (lisocabtagene maraleucel)